BACKGROUND: Lipoprotein(a) [Lp(a)] is an established risk factor for coronary disease and stroke, but mechanisms underlying this association are unknown. We examined the association of Lp(a) with early atherosclerosis by using conventional epidemiologic analysis and a Mendelian randomization analysis. The latter utilized genetic variants that are associated with Lp(a) to estimate causal effect. METHODS: A prospective population-based cohort study of 939 men and 1141 women was conducted. Lp(a) was measured repeatedly at mean ages 17 and 38 years. Measurements of carotid intima-media thickness (IMT) and brachial flow-mediated dilation (FMD) at mean ages 32 and 38 years were used to determine the level and 6-year progression of subclinical atherosclerosis. Lp(a)-related genetic variant, rs783147, was identified by a genome wide association analysis (P = 3.1 × 10⁻⁵⁸), and a genetic score was constructed based on 10 Lp(a)-related variants. Mendelian randomization test was performed using a two-stage instrumental variables analysis. RESULTS: rs783147 and the genetic score were strong instruments for nonconfounded Lp(a) levels (F-statistics 269.6 and 446.0 in the first-stage instrumental variable analysis). However, Lp(a) levels were not associated with the levels of or change in IMT or FMD in any of the conventional and instrumental variables tests. The null finding was observed both with rs783147 and the genetic score as instruments and remained unchanged after adjustment for clinical characteristics, such as age, sex, HDL and LDL cholesterol, ApoB, systolic and diastolic blood pressure, diabetes and smoking. CONCLUSIONS: Data from conventional and Mendelian randomization analyses provide no support for early atherogenic effects of increased Lp(a) levels.
BACKGROUND:Lipoprotein(a) [Lp(a)] is an established risk factor for coronary disease and stroke, but mechanisms underlying this association are unknown. We examined the association of Lp(a) with early atherosclerosis by using conventional epidemiologic analysis and a Mendelian randomization analysis. The latter utilized genetic variants that are associated with Lp(a) to estimate causal effect. METHODS: A prospective population-based cohort study of 939 men and 1141 women was conducted. Lp(a) was measured repeatedly at mean ages 17 and 38 years. Measurements of carotid intima-media thickness (IMT) and brachial flow-mediated dilation (FMD) at mean ages 32 and 38 years were used to determine the level and 6-year progression of subclinical atherosclerosis. Lp(a)-related genetic variant, rs783147, was identified by a genome wide association analysis (P = 3.1 × 10⁻⁵⁸), and a genetic score was constructed based on 10 Lp(a)-related variants. Mendelian randomization test was performed using a two-stage instrumental variables analysis. RESULTS:rs783147 and the genetic score were strong instruments for nonconfounded Lp(a) levels (F-statistics 269.6 and 446.0 in the first-stage instrumental variable analysis). However, Lp(a) levels were not associated with the levels of or change in IMT or FMD in any of the conventional and instrumental variables tests. The null finding was observed both with rs783147 and the genetic score as instruments and remained unchanged after adjustment for clinical characteristics, such as age, sex, HDL and LDL cholesterol, ApoB, systolic and diastolic blood pressure, diabetes and smoking. CONCLUSIONS: Data from conventional and Mendelian randomization analyses provide no support for early atherogenic effects of increased Lp(a) levels.
Authors: Olli T Raitakari; Markus Juonala; Mika Kähönen; Leena Taittonen; Tomi Laitinen; Noora Mäki-Torkko; Mikko J Järvisalo; Matti Uhari; Eero Jokinen; Tapani Rönnemaa; Hans K Akerblom; Jorma S A Viikari Journal: JAMA Date: 2003-11-05 Impact factor: 56.272
Authors: P J Schreiner; G Heiss; H A Tyroler; J D Morrisett; C E Davis; R Smith Journal: Arterioscler Thromb Vasc Biol Date: 1996-03 Impact factor: 8.311
Authors: G L Burke; G W Evans; W A Riley; A R Sharrett; G Howard; R W Barnes; W Rosamond; R S Crow; P M Rautaharju; G Heiss Journal: Stroke Date: 1995-03 Impact factor: 7.914
Authors: Costan G Magnussen; Harri Niinikoski; Markus Juonala; Mika Kivimäki; Tapani Rönnemaa; Jorma S A Viikari; Olli Simell; Olli T Raitakari Journal: Pediatr Nephrol Date: 2011-08-30 Impact factor: 3.714
Authors: Gretchen E Volpe; Alice M Tang; Joseph F Polak; Alexandra Mangili; Sally C Skinner; Christine A Wanke Journal: J Acquir Immune Defic Syndr Date: 2013-09-01 Impact factor: 3.731
Authors: Evropi Theodoratou; Tom Palmer; Lina Zgaga; Susan M Farrington; Paul McKeigue; Farhat V N Din; Albert Tenesa; George Davey-Smith; Malcolm G Dunlop; Harry Campbell Journal: PLoS One Date: 2012-06-06 Impact factor: 3.240
Authors: Salome Mack; Stefan Coassin; Rico Rueedi; Noha A Yousri; Ilkka Seppälä; Christian Gieger; Sebastian Schönherr; Lukas Forer; Gertraud Erhart; Pedro Marques-Vidal; Janina S Ried; Gerard Waeber; Sven Bergmann; Doreen Dähnhardt; Andrea Stöckl; Olli T Raitakari; Mika Kähönen; Annette Peters; Thomas Meitinger; Konstantin Strauch; Ludmilla Kedenko; Bernhard Paulweber; Terho Lehtimäki; Steven C Hunt; Peter Vollenweider; Claudia Lamina; Florian Kronenberg Journal: J Lipid Res Date: 2017-05-16 Impact factor: 5.922